Filing step-change
OLPCL · 2026-08
Quarterly observations that moved versus the prior period in 2026-08. Facts only — not a call to act.
Narrative date 2026-08-31 · Evidence medium
Omicron Pharmaceuticals (OLPCL) Sees Improvement in Gross Margin and Revenue Growth, Despite Decline in Daily Volume and Close Price.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 11.87 % | -29.99 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | -29.99 % | -2.82 | ▼ |
Cite this
Source: Samhati filing step-change for OLPCL (2026-08). Observation: Omicron Pharmaceuticals (OLPCL) Sees Improvement in Gross Margin and Revenue Growth, Despite Decline in Daily Volume and Close Price. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/olpcl/q/2026-08
Other periods